BioSpace News Archive

Infinity Pharmaceuticals Provides Additional Information on MARIO-8 Study Evaluating Eganelisib in Combination with the PD-1 Targeted Checkpoint Inhibitor Pembrolizumab (KEYTRUDA ® ) in Patients with Squamous Cell Cancer of the Head and Neck (SCCHN).

The March of Dimes National Board of Trustees announced the appointment of Dr. Elizabeth Cherot as the organization’s new President and Chief Executive Officer, effective July 17.

Cellinfinity Bio announced the publication of MAJESTIC, a technology that efficiently and with high cell health introduces genes into human genome, independent of CRISPR and lentiviral methods.

Adaptive Biotechnologies Corporation announced it will report financial results for the second quarter 2023 after market close on Wednesday, August 2, 2023.

Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced the grant of stock options to purchase 28,917 shares of its common stock to five new employees.

Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostic products, will report its financial results for the second quarter of 2023 on Thursday, August 3, 2023, following the close of the market.

Better Therapeutics, Inc., a pioneer in developing software to treat cardiometabolic diseases, announced that the Food and Drug Administration authorized AspyreRx™, a prescription-only digital therapeutic treatment indicated to provide cognitive behavioral therapy to patients 18 years or older with type 2 diabetes.

Ocuphire Pharma, Inc., announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, approved an equity award under Ocuphire’s 2021 Inducement Plan, as a material inducement to a new hire in connection with such new hire’s employment with the Company effective on July 10, 2023.

Mirum Pharmaceuticals, Inc. announced that on July 10, 2023, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 44,850 shares of common stock and 22,430 restricted stock units to ten new employees under Mirum’s 2020 Inducement Plan.

Clover Biopharmaceuticals, Ltd., a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, provided updates on business and R&D pipeline development.